Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
32.91
+0.63 (1.95%)
At close: Mar 4, 2026, 4:00 PM EST
32.71
-0.20 (-0.61%)
After-hours: Mar 4, 2026, 7:08 PM EST
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 37.38, with a low estimate of 26 and a high estimate of 45. The average target predicts an increase of 13.58% from the current stock price of 32.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 5 | 5 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $40 → $41 | Buy | Reiterates | $40 → $41 | +24.58% | Mar 4, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $38 → $42 | Strong Buy | Maintains | $38 → $42 | +27.62% | Feb 18, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $36 → $45 | Strong Buy | Maintains | $36 → $45 | +36.74% | Feb 9, 2026 |
| Barclays | Barclays | Buy Maintains $35 → $38 | Buy | Maintains | $35 → $38 | +15.47% | Jan 30, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +21.54% | Jan 29, 2026 |
Financial Forecast
Revenue This Year
17.11B
from 17.26B
Decreased by -0.89%
Revenue Next Year
17.54B
from 17.11B
Increased by 2.51%
EPS This Year
2.76
from 1.21
Increased by 128.17%
EPS Next Year
3.10
from 2.76
Increased by 12.19%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.9B | 18.5B | |
| Avg | 17.1B | 17.5B | |
| Low | 16.2B | 16.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.9% | 8.0% | |
| Avg | -0.9% | 2.5% | |
| Low | -6.3% | -3.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.97 | 3.32 | |
| Avg | 2.76 | 3.10 | |
| Low | 2.56 | 2.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 145.6% | 20.2% | |
| Avg | 128.2% | 12.2% | |
| Low | 112.0% | 1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.